A dual macrophage polarizer conjugate for synergistic melanoma therapy.
暂无分享,去创建一个
[1] S. Mitragotri,et al. Hyaluronic Acid Conjugates of Vorinostat and Bexarotene for Treatment of Cutaneous Malignancies , 2020 .
[2] S. Mitragotri,et al. Erythrocyte-driven immunization via biomimicry of their natural antigen-presenting function , 2020, Proceedings of the National Academy of Sciences.
[3] M. Sokolsky-Papkov,et al. High-capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma. , 2020, Science advances.
[4] S. Mitragotri,et al. Cellular backpacks for macrophage immunotherapy , 2020, Science Advances.
[5] J. Carucci,et al. Current Research in Melanoma and Aggressive Nonmelanoma Skin Cancer , 2020, Facial Plastic Surgery.
[6] Xikun Zhou,et al. Tumor-Associated Macrophages: Recent Insights and Therapies , 2020, Frontiers in Oncology.
[7] Yichao Chen,et al. High Loading of Hydrophobic and Hydrophilic Agents via Small Immunostimulatory Carrier for Enhanced Tumor Penetration and Combinational Therapy , 2020, Theranostics.
[8] S. Mitragotri,et al. Macrophage‐Mediated Delivery of Hypoxia‐Activated Prodrug Nanoparticles , 2019, Advanced Therapeutics.
[9] L. Sansing,et al. Bexarotene Enhances Macrophage Erythrophagocytosis and Hematoma Clearance in Experimental Intracerebral Hemorrhage , 2019, Stroke.
[10] S. Mitragotri,et al. Drug delivery to macrophages: A review of targeting drugs and drug carriers to macrophages for inflammatory diseases. , 2019, Advanced drug delivery reviews.
[11] R. Carvajal,et al. Novel Targets for the Treatment of Melanoma , 2019, Current Oncology Reports.
[12] A. Kulkarni,et al. CSF1R‐ and SHP2‐Inhibitor‐Loaded Nanoparticles Enhance Cytotoxic Activity and Phagocytosis in Tumor‐Associated Macrophages , 2019, Advanced materials.
[13] S. Fukushima,et al. Bexarotene Reduces Production of CCL22 From Tumor-Associated Macrophages in Cutaneous T-Cell Lymphoma , 2019, Front. Oncol..
[14] S. Walmsley,et al. Inflammation and Hypoxia: HIF and PHD Isoform Selectivity. , 2019, Trends in molecular medicine.
[15] D. Ford,et al. TLR8-Mediated Metabolic Control of Human Treg Function: A Mechanistic Target for Cancer Immunotherapy. , 2019, Cell metabolism.
[16] Kimberly R. Jordan,et al. Targeting myeloid‐derived suppressor cells using all‐trans retinoic acid in melanoma patients treated with Ipilimumab , 2018, International immunopharmacology.
[17] Shiladitya Sengupta,et al. A designer self-assembled supramolecule amplifies macrophage immune responses against aggressive cancer , 2018, Nature Biomedical Engineering.
[18] Michael F. Cuccarese,et al. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy , 2018, Nature Biomedical Engineering.
[19] Xian Wang,et al. HIF1α-Induced Glycolysis Metabolism Is Essential to the Activation of Inflammatory Macrophages , 2017, Mediators of inflammation.
[20] S. Mitragotri,et al. A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer , 2017, Journal of controlled release : official journal of the Controlled Release Society.
[21] P. Allavena,et al. Targeting tumor associated macrophages: The new challenge for nanomedicine. , 2017, Seminars in immunology.
[22] Q. Luo,et al. Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages. , 2017, ACS nano.
[23] S. Mitragotri,et al. A review on engineering polymer drug conjugates to improve combination chemotherapy , 2017 .
[24] Ou Sha,et al. Anti-tumor Activity of Toll-Like Receptor 7 Agonists , 2017, Front. Pharmacol..
[25] A. Letai,et al. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages , 2017, Nature.
[26] Ralph Weissleder,et al. Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging , 2017, Nature Communications.
[27] I. Stratford,et al. The CD44‐Mediated Uptake of Hyaluronic Acid‐Based Carriers in Macrophages , 2017, Advanced healthcare materials.
[28] Alberto Mantovani,et al. Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.
[29] S. Mehrotra,et al. Ccl22 Diverts T Regulatory Cells and Controls the Growth of Melanoma. , 2016, Cancer research.
[30] Yukio Fujiwara,et al. Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy. , 2016, Advanced drug delivery reviews.
[31] Li Li,et al. Preparation, in vitro and in vivo evaluation of bexarotene nanocrystals with surface modification by folate-chitosan conjugates , 2016, Drug delivery.
[32] M. Amiji,et al. Modulation of Macrophage Functional Polarity towards Anti-Inflammatory Phenotype with Plasmid DNA Delivery in CD44 Targeting Hyaluronic Acid Nanoparticles , 2015, Scientific Reports.
[33] Shiyin Yao,et al. Enhancement of the Immunostimulatory Activity of a TLR7 Ligand by Conjugation to Polysaccharides. , 2015, Bioconjugate chemistry.
[34] Ram I Mahato,et al. Nanoparticle-mediated drug delivery for treating melanoma. , 2015, Nanomedicine.
[35] S. Mitragotri,et al. Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[36] H. Byrne,et al. Dual Targeted Immunotherapy via In Vivo Delivery of Biohybrid RNAi‐Peptide Nanoparticles to Tumor‐Associated Macrophages and Cancer Cells , 2015, Advanced functional materials.
[37] Jean Felix Mukerabigwi,et al. Precise Ratiometric Control of Dual Drugs through a Single Macromolecule for Combination Therapy. , 2015, Molecular pharmaceutics.
[38] Brian Ruffell,et al. Macrophages and therapeutic resistance in cancer. , 2015, Cancer cell.
[39] P. Allavena,et al. The interaction of anticancer therapies with tumor-associated macrophages , 2015, The Journal of experimental medicine.
[40] P. Sharma,et al. The future of immune checkpoint therapy , 2015, Science.
[41] P. Murray,et al. Understanding Local Macrophage Phenotypes In Disease: Modulating macrophage function to treat cancer , 2015, Nature Medicine.
[42] R. Satchi‐Fainaro,et al. Anticancer polymeric nanomedicine bearing synergistic drug combination is superior to a mixture of individually-conjugated drugs. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[43] S. Gordon,et al. The M1 and M2 paradigm of macrophage activation: time for reassessment , 2014, F1000prime reports.
[44] Christina S. Leslie,et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression , 2013, Nature Medicine.
[45] Thomas A. Wynn,et al. Macrophage biology in development, homeostasis and disease , 2013, Nature.
[46] C. Lewis,et al. Macrophage regulation of tumor responses to anticancer therapies. , 2013, Cancer cell.
[47] C. Hotz,et al. Systemic cancer immunotherapy with Toll-like receptor 7 agonists , 2012, Oncoimmunology.
[48] C. Hotz,et al. Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance. , 2011, Cancer research.
[49] R. Schreiber,et al. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.
[50] Hailing Lu,et al. The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system , 2011, Expert review of clinical pharmacology.
[51] K. Ulbrich,et al. Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. , 2009, Biomaterials.
[52] Z. Berneman,et al. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. , 2008, The oncologist.
[53] V. Singh,et al. The role of nitric oxide in inflammatory reactions. , 2007, FEMS immunology and medical microbiology.
[54] M. Fishman,et al. Mechanism of all-trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells. , 2007, Cancer research.
[55] P. Nowell,et al. Evidence of myeloid differentiation in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene , 2007, Cancer biology & therapy.
[56] R. Foà,et al. The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response. , 2003, Cancer research.
[57] D. Irvine,et al. Amphiphilic nanoparticle delivery enhances the anticancer efficacy of a TLR7 ligand via local immune activation. , 2019, Biomaterials.
[58] Yao-Xin Lin,et al. Polymeric nanoparticles promote macrophage reversal from M2 to M1 phenotypes in the tumor microenvironment. , 2017, Biomaterials.